Lateral Node Metastasis in Low Rectal Cancer As a Hallmark to Predict Recurrence Patterns

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2024 Oct 14

PMID 39402391

Authors

Eiji Shinto

Hideyuki Ike

Masaaki Ito

Keiichi Takahashi

Masayuki Ohue

Yukihide Kanemitsu

Takeshi Suto

Tetsushi Kinugasa

Jun Watanabe

Jin-Ichi Hida

Michio Itabashi

Heita Ozawa

Hiroaki Nozawa

Yojiro Hashiguchi

Kazuo Hase

Kenichi Sugihara

Yoichi Ajioka

Affiliations

Soon will be listed here.

Abstract

Background: Lateral node metastasis confers a poor prognosis in rectal cancer. Several multidisciplinary treatments have been proposed with favorable outcomes. However, appropriate neoadjuvant/adjuvant treatments or follow-up plans based on information about the probable recurrence site have not been specified. We aimed to clarify the distinctive features of recurrence patterns for lateral node-positive low rectal cancer according to the lateral and mesorectal lymph node status.

Methods: We retrospectively analyzed 508 patients with stage III low rectal cancer who underwent lateral node dissection. We investigated the impact of lateral and mesorectal lymph node status on site-specific recurrence rates and patient survival.

Results: Analyses for relapse-free survival revealed the prognostic impact of lateral node positivity in stage III low rectal cancer (p < 0.0001). Lateral node-positive patients exhibited higher risk of overall recurrence, local recurrence, and recurrence in extra-regional nodes than lateral node-negative patients (p < 0.0001, p = 0.001, and p < 0.0001, respectively). However, lateral node positivity was not statistically associated with a hematogenous recurrence rate. In lateral node-positive patients, both tumor-node-metastasis (TNM)-N status and number of lateral nodes involved were revealed as significant prognostic factors (p < 0.0001, both). In addition, the number of lateral nodes involved could be a discriminatory indicator of probabilities of local recurrence and recurrence in extra-regional nodes (p = 0.02, and p < 0.0001, respectively).

Conclusions: Lateral node-positive low rectal cancer exhibits higher local recurrence and extra-regional node recurrence rates that correlate with the number of lateral nodes involved.

References

Kanemitsu Y, Komori K, Shida D, Ochiai H, Tsukamoto S, Kinoshita T . Potential impact of lateral lymph node dissection (LLND) for low rectal cancer on prognoses and local control: A comparison of 2 high-volume centers in Japan that employ different policies concerning LLND. Surgery. 2017; 162(2):303-314. DOI: 10.1016/j.surg.2017.02.005. View

Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K . Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease?. Ann Surg. 2012; 255(6):1129-34. DOI: 10.1097/SLA.0b013e3182565d9d. View

Yamai D, Shimada Y, Nakano M, Ozeki H, Matsumoto A, Abe K . Clinical significance of metastatic tumor deposit foci in rectal cancer in the lateral pelvic lymph node area. Int J Clin Oncol. 2023; 28(10):1388-1397. DOI: 10.1007/s10147-023-02391-1. View

Hiyoshi Y, Miyamoto Y, Kiyozumi Y, Eto K, Nagai Y, Iwatsuki M . Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Clin Oncol. 2019; 25(1):110-117. DOI: 10.1007/s10147-019-01523-w. View

Oki E, Ando K, Kasagi Y, Zaitsu Y, Sugiyama M, Nakashima Y . Recent advances in multidisciplinary approach for rectal cancer. Int J Clin Oncol. 2015; 20(4):641-9. DOI: 10.1007/s10147-015-0858-8. View

Geppert B, Lonnerfors C, Bollino M, Arechvo A, Persson J . A study on uterine lymphatic anatomy for standardization of pelvic sentinel lymph node detection in endometrial cancer. Gynecol Oncol. 2017; 145(2):256-261. DOI: 10.1016/j.ygyno.2017.02.018. View

Yuen K, Miura T, Sakai I, Kiyosue A, Yamashita M . Intraoperative Fluorescence Imaging for Detection of Sentinel Lymph Nodes and Lymphatic Vessels during Open Prostatectomy using Indocyanine Green. J Urol. 2015; 194(2):371-7. DOI: 10.1016/j.juro.2015.01.008. View

Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S . Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol. 2018; 37(1):33-43. PMC: 6366816. DOI: 10.1200/JCO.18.00032. View

Akiyoshi T, Toda S, Tominaga T, Oba K, Tomizawa K, Hanaoka Y . Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer. BJS Open. 2019; 3(6):822-829. PMC: 6887909. DOI: 10.1002/bjs5.50194. View

10.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

11.

Peeters K, Marijnen C, Nagtegaal I, Kranenbarg E, Putter H, Wiggers T . The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007; 246(5):693-701. DOI: 10.1097/01.sla.0000257358.56863.ce. View

12.

Schrag D, Weiser M, Goodman K, Gonen M, Hollywood E, Cercek A . Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014; 32(6):513-8. PMC: 5795691. DOI: 10.1200/JCO.2013.51.7904. View

13.

Fernandez-Martos C, Brown G, Estevan R, Salud A, Montagut C, Maurel J . Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial. Oncologist. 2014; 19(10):1042-3. PMC: 4201001. DOI: 10.1634/theoncologist.2014-0233. View

14.

Patel U, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E . MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017; 28(2):344-353. DOI: 10.1093/annonc/mdw616. View

15.

Hamaguchi T, Shirao K, Moriya Y, Yoshida S, Kodaira S, Ohashi Y . Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). Cancer Chemother Pharmacol. 2010; 67(3):587-96. DOI: 10.1007/s00280-010-1358-1. View

16.

Gerard J, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne P . Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012; 30(36):4558-65. DOI: 10.1200/JCO.2012.42.8771. View

17.

Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C . Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol. 2015; 26(8):1722-8. DOI: 10.1093/annonc/mdv223. View

18.

Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E . Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019; 30(8):1298-1303. DOI: 10.1093/annonc/mdz186. View